Effect of Anti-Siglec-F Antibody and Reactive Oxygen Species Blocking on Histamine Release in Urinary Bladder of Ovalbumin-Treated Mice
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Sialic acid-binding Ig-like lectin (Siglec) is an immune inhibitory receptor that plays a role in the negative regulation of the activation of immune cells. This study aimed to evaluate the effects of anti-Siglec-F on plasma and urinary histamine levels in ovalbumin (OVA)-challenged urinary bladder in mice. Methods: Thirty BALB/c mice were used. In group I (control group, n=5), mice were sensitized with OVA and challenged with saline. In group II (OVA challenge group, n=5), OVA was used for intraperitoneal sensitization and intravesical challenge. The challenged mice in group III (control immunoglobulin G [IgG] group, n=5) and those in group IV (anti-Siglec-F group, n=5) were intraperitoneally pretreated with rabbit control IgG or anti-Siglec-F antibody, respectively. In groups V (N-acetylcysteine[NAC] in OVA challenge group, n=5) and VI (control NAC only, n=5), mice were pretreated with NAC. Results: Urinary histamine concentrations were significantly higher 7 days after intravesical OVA challenge (P<0.01), whereas plasma histamine levels were not. Pretreatment with anti-Siglec-F antibody significantly prevented the increase in urinary histamine release (P<0.05), whereas pretreatment with the IgG antibody control did not. Also, pretreatment of the OVA challenge group with NAC did not affect the histamine concentration in either urine or plasma. Conclusions: Systemic anti-Siglec-F treatment showed anti-allergic effects at least on local histamine release, particularly in the lower urinary bladder.
Abstract
Purpose: Sialic acid-binding Ig-like lectin (Siglec) is an immune inhibitory receptor that plays a role in the negative regulation of the activation of immune cells. This study aimed to evaluate the effects of anti-Siglec-F on plasma and urinary histamine levels in ovalbumin (OVA)-challenged urinary bladder in mice. Methods: Thirty BALB/c mice were used. In group I (control group, n=5), mice were sensitized with OVA and challenged with saline. In group II (OVA challenge group, n=5), OVA was used for intraperitoneal sensitization and intravesical challenge. The challenged mice in group III (control immunoglobulin G [IgG] group, n=5) and those in group IV (anti-Siglec-F group, n=5) were intraperitoneally pretreated with rabbit control IgG or anti-Siglec-F antibody, respectively. In groups V (N-acetylcysteine[NAC] in OVA challenge group, n=5) and VI (control NAC only, n=5), mice were pretreated with NAC. Results: Urinary histamine concentrations were significantly higher 7 days after intravesical OVA challenge (P<0.01), whereas plasma histamine levels were not. Pretreatment with anti-Siglec-F antibody significantly prevented the increase in urinary histamine release (P<0.05), whereas pretreatment with the IgG antibody control did not. Also, pretreatment of the OVA challenge group with NAC did not affect the histamine concentration in either urine or plasma. Conclusions: Systemic anti-Siglec-F treatment showed anti-allergic effects at least on local histamine release, particularly in the lower urinary bladder.
참고문헌 (15)
- Bochner BS, "Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors", Clin Exp Allergy, 39, pp.317~324 (2009)
- O’Reilly MK, "Siglecs as targets for therapy in immune-cell-mediated disease", Trends Pharmacol Sci, 30, pp.240~248 (2009)
- Tateno H, "Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity", Mol Cell Biol, 27, pp.5699~5710 (2007)
- Song DJ, "Anti-Siglec-F antibody reduces allergen-induced eosinophilic inflammation and airway remodeling", J Immunol, 183, pp.5333~5341 (2009)
- Zhang M, "Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils", Blood, 109, pp.4280~4287 (2007)
- 박창신, "Potential Targeting of Siglecs, Mast Cell Inhibitory Receptors, in Interstitial Cystitis", International Neurourology Journal, 15(2), pp.61~63 (2011), 대한배뇨장애요실금학회
- 진롱후, "Intravesical PGE2 Administration in Conscious Rats as an Experimental Model of Detrusor Overactivity Observed by Simultaneous Registrations of Intravesical and Intraabdominal Pressures", International Neurourology Journal, 14(2), pp.69~77 (2010), 대한배뇨장애요실금학회
- Kim YH, "Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis", ALLERGY, 67(2), pp.183~190 (2012), BLACKWELL MUNKSGAARD
- Ahluwalia A, "Ovalbumin-induced neurogenic inflammation in the bladder of sensitized rats", Br J Pharmacol, 124, pp.190~196 (1998)
- Bergstrand H, "Human basophil histamine release is differently affected by inhibitors of calmodulin, diacylglycerol kinase and peptidyl prolyl cis-trans isomerase in a secretagogue specific manner", Allergy, 47(4), pp.353~361 (1992)
- Tateno H, "Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6’-sulfo-sialyl Lewis X as a preferred glycan ligand", Glycobiology, 15, pp.1125~1135 (2005)
- 송대진, "Anti-Siglec-F antibody inhibits oral egg allergen induced intestinal eosinophilic inflammation in a mouse model", CLINICAL IMMUNOLOGY, 131(1), pp.157~169, ACADEMIC PRESS INC ELSEVIER SCIENCE
- Crocker PR, "Siglecs and their roles in the immune system", Nat Rev Immunol, 7, pp.255~266 (2007)
- Yokoi H, "Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells", Allergy, 61, pp.769~776 (2006)
- Kiwamoto T, "Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions", Pharmacol Ther, 135, pp.327~336 (2012)